12:00 AM
 | 
Apr 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ACH-3102: Phase II started

Achillion began the international Phase II 007 trial evaluating an all-oral regimen of ACH-3102 plus sovaprevir and ribavirin in up to 50 treatment-naive patients with chronic HCV infection. Patients...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >